A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
LN-145 is a ready-to-infuse, autologous TIL therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI and further optimized by Iovance for the treatment of patients with metastatic NSCLC. The cell transfer therapy used in this study involves patients receiving an NMA lymphocyte depleting preparative regimen, followed by infusion of autologous TIL, then finally followed by the administration of IL-2.
To evaluate the efficacy of LN-145 in patients with metastatic NSCLC without an
actionable driver mutation who have disease progression on or following a single
line of approved systemic therapy consisting of combined immune checkpoint
inhibitor(s) (CPI[s]) + chemotherapy ± bevacizumab, as determined by objective
response rate (ORR), using the RECIST v1.1, as assessed by the Independent
Review Committee (IRC) (Cohorts 1 and 2) or by the Investigator (Cohorts 3 and 4)
To evaluate the efficacy of LN-145, as determined by ORR, using
RECIST v1.1, as assessed by the Investigator (Cohorts 1 and 2 only)
To further evaluate the efficacy of LN-145 using complete response (CR) rate;
duration of response (DOR); disease control rate (DCR); progression-free
survival (PFS) using RECIST v1.1, as assessed by the IRC (Cohorts 1 and 2
only) and Investigator (all cohorts); and overall survival (OS)
To characterize the safety profile of LN-145 in NSCLC patients, as measured
by the incidence of Grade ≥ 3 treatment-emergent adverse events (TEAEs)
For Cohort 3 only: To evaluate the efficiency of generating LN-145 from
tumor core biopsies
To evaluate the persistence of LN-145 and to identify immune correlates that
may correlate with response, outcome, and toxicity variables
To assess respective, indication-specific, health-related quality of life
Confirmed histologic diagnosis of Non-Small-Cell Lung Carcinoma confirmation
Have received a single line of systemic therapy that included CPI and chemotherapy with documented radiographic disease progression on or following this single line of systemic therapy
LVEF > 45%, NYHA Class 1; cardiac stress test required
FEV1>50% or FEV1/FVC>0.7 (6 min walk test if unable to perform or unreliable spirometry)
At least 1 resectable lesion
Previously irradiated lesion must have radiographic progression prior to harvest
Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and an estimated life expectancy of > 6 months
Patients of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and for 12 months after receiving all protocol-related therapy.
Patients who have known oncogene driver mutations (eg, EGFR, ALK, ROS) which are sensitive to targeted therapies
Patients who have symptomatic and/or untreated brain metastases
Patients who have organ allograft or prior cell transfer within the past 20 years
Patients who are on systemic steroid therapy > 10 mg/day of prednisone or other steroid equivalent. Patients receiving steroids as replacement therapy for adrenocortical insufficiency at > Patients who have any form of primary immunodeficiency
Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment
Patients who have had another primary malignancy within the previous 3 years
Participation in another interventional clinical study within 21 days of the initiation of treatment
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub